New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo
WFLX Fox 29,
SOURCE Eli Lilly and Company Phase 3 trial results published in Annals of the Rheumatic Diseases demonstrate baricitinib's…